CRSP
Income statement / Annual
Last year (2023), CRISPR Therapeutics AG's total revenue was $370.00 M,
an increase of 84,762.39% from the previous year.
In 2023, CRISPR Therapeutics AG's net income was -$153.61 M.
See CRISPR Therapeutics AG’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$370.00 M
|
$436,000.00
|
$913.08 M
|
$543,000.00
|
$289.59 M
|
$3.12 M
|
$41.00 M
|
$5.16 M
|
$247,000.00
|
$0.00
|
| Cost of Revenue |
$130.25 M |
$110.25 M |
$17.95 M |
$269.41 M |
$179.36 M |
$113.77 M |
$69.80 M |
$42.24 M |
$12.57 M |
$1.51 M |
| Gross Profit |
$239.75 M |
-$109.81 M |
$895.13 M |
-$268.86 M |
$110.23 M |
-$110.65 M |
-$28.80 M |
-$37.07 M |
-$12.33 M |
-$1.51 M |
| Gross Profit Ratio |
0.65 |
-251.87 |
0.98 |
-495.15 |
0.38 |
-35.42 |
-0.7 |
-7.18 |
-49.9 |
0 |
| Research and Development
Expenses |
$387.33 M
|
$461.65 M
|
$438.63 M
|
$266.95 M
|
$179.36 M
|
$113.77 M
|
$69.80 M
|
$42.24 M
|
$12.57 M
|
$1.51 M
|
| General & Administrative
Expenses |
$76.16 M
|
$102.46 M
|
$102.80 M
|
$88.21 M
|
$63.49 M
|
$48.29 M
|
$35.85 M
|
$31.06 M
|
$13.40 M
|
$5.11 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$76.16 M
|
$102.46 M
|
$102.80 M
|
$88.21 M
|
$63.49 M
|
$48.29 M
|
$35.85 M
|
$31.06 M
|
$13.40 M
|
$5.11 M
|
| Other Expenses |
$71.82 M |
-$762,000.00 |
-$1.88 M |
-$176,000.00 |
$20.57 M |
-$5.49 M |
-$197,000.00 |
$78.51 M |
$16,000.00 |
-$236,000.00 |
| Operating Expenses |
$462.29 M |
$563.35 M |
$539.55 M |
$354.98 M |
$242.85 M |
$162.07 M |
$105.65 M |
$73.29 M |
$25.98 M |
$6.63 M |
| Cost And Expenses |
$592.54 M |
$673.60 M |
$539.55 M |
$354.98 M |
$242.85 M |
$162.07 M |
$105.65 M |
$73.29 M |
$25.98 M |
$6.63 M |
| Interest Income |
$0.00 |
$22.66 M |
$0.00 |
$0.00 |
$10.03 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
-$46.83 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$8.05 M |
$108,000.00 |
$0.00 |
| Depreciation &
Amortization |
$19.84 M
|
$24.17 M
|
$17.95 M
|
$9.18 M
|
$4.73 M
|
$3.52 M
|
$3.02 M
|
$1.00 M
|
$127,000.00
|
$38,000.00
|
| EBITDA |
-$202.70 M
|
-$673.16 M
|
$373.53 M
|
-$345.25 M
|
$46.74 M
|
-$158.94 M
|
-$61.62 M
|
-$25.23 M
|
-$25.59 M
|
-$6.83 M
|
| EBITDA Ratio |
-0.55 |
-1543.95 |
0.41 |
-635.82 |
0.16 |
-50.88 |
-1.5 |
-4.88 |
-103.59 |
0 |
| Operating Income Ratio
|
-0.6
|
-1543.95
|
0.41
|
-652.73
|
0.16
|
-50.88
|
-1.58
|
-13.19
|
-104.17
|
0
|
| Total Other
Income/Expenses Net |
$71.82 M
|
$22.66 M
|
$6.00 M
|
$6.38 M
|
$20.57 M
|
-$5.49 M
|
-$1.96 M
|
$53.46 M
|
$16,000.00
|
-$236,000.00
|
| Income Before Tax |
-$150.72 M |
-$650.50 M |
$379.53 M |
-$348.06 M |
$67.31 M |
-$164.43 M |
-$66.61 M |
-$22.72 M |
-$25.82 M |
-$6.86 M |
| Income Before Tax Ratio
|
-0.41
|
-1491.97
|
0.42
|
-640.99
|
0.23
|
-52.63
|
-1.62
|
-4.4
|
-104.54
|
0
|
| Income Tax Expense |
$2.89 M |
-$325,000.00 |
$1.87 M |
$809,000.00 |
$448,000.00 |
$553,000.00 |
$1.75 M |
$484,000.00 |
$7,000.00 |
-$63,000.00 |
| Net Income |
-$153.61 M |
-$650.18 M |
$377.66 M |
-$348.87 M |
$66.86 M |
-$164.98 M |
-$68.36 M |
-$23.20 M |
-$25.83 M |
-$6.80 M |
| Net Income Ratio |
-0.42 |
-1491.23 |
0.41 |
-642.48 |
0.23 |
-52.81 |
-1.67 |
-4.49 |
-104.57 |
0 |
| EPS |
-1.94 |
-8.36 |
4.97 |
-5.29 |
1.23 |
-3.44 |
-1.71 |
-1.89 |
-0.88 |
-0.23 |
| EPS Diluted |
-1.94 |
-8.36 |
4.7 |
-5.29 |
1.17 |
-3.44 |
-1.71 |
-1.89 |
-0.88 |
-0.23 |
| Weighted Average Shares
Out |
$79.22 M
|
$77.75 M
|
$75.95 M
|
$65.95 M
|
$54.39 M
|
$47.96 M
|
$39.97 M
|
$12.26 M
|
$29.30 M
|
$29.30 M
|
| Weighted Average Shares
Out Diluted |
$79.22 M
|
$77.75 M
|
$80.39 M
|
$65.95 M
|
$56.93 M
|
$47.96 M
|
$40.06 M
|
$12.26 M
|
$29.30 M
|
$29.30 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
